Keepin touch

Whether you have a question, comment, suggestion or any problem falling within the competence of the Government, send us your message and we will try to respond as soon as possible. If your problem does not fall within our competence, we will forward your message to the competent institution.

The Government of the Republic of Serbia

In the service of citizens

Bill on amendments to law aimed at improving population policy adopted

Belgrade, 23 December 2021

The Serbian government adopted today the Bill on Amendments to the Law on Financial Support to Families with Children, in order to improve the conditions for meeting their basic needs, encourage childbirth and provide support to financially disadvantaged families, families with children with disabilities. children with disabilities, as well as children without parental care.

With these changes, the parental allowance has been increased from the previous RSD 100,000 to RSD 300,000, it is made as one-off payment and refers to the first child born on 1 January 2022 and later.

Another new measure of population policy is the new right, which is defined as the right to funds for construction, participation in the purchase, i.e. the purchase of a family-residential building or apartment based on the birth of a child.

This right can be exercised by every mother for a child born on 1 January 2022 and later, provided that she is a citizen of the Republic of Serbia, has a permanent residence in the Republic of Serbia and acquires for the first time a family building or apartment in Serbia.

The right can also be exercised by a mother who is a foreign citizen and has the status of a permanent resident alien, if the child was born in the territory of the Republic of Serbia and / or is a citizen of the Republic of Serbia.

Exceptionally, in the event of the death of the child's mother, the child's father may exercise the right.

The government adopted the Conclusion on giving consent that the Ministry of Health takes all measures within its competence with the aim of employing the best 200 medical faculties graduates in health institutions in the Republic of Serbia.

The government adopted the Conclusion on giving consent that the Ministry of Health takes all measures within its competence with the aim of employing the best 500 medical high school graduates in health institutions in the Republic of Serbia.

With these decisions, the Serbian government wants to contribute to improving the age structure of staff in health institutions and to improving the level of health care by hiring the best health workers with higher and secondary education.

The government adopted a decision on the termination of mandate of Police Director Vladimir Rebic.

The government adopted the Conclusion on recommendations to institutions of higher education regarding students who have become parents and are prevented from attending classes, fulfilling pre-examination obligations and taking exams.

In order to encourage the birth rate and motivate students to decide to have children, the government recommended measures to higher education institutions founded by the Republic of Serbia, which relate to the conditions for enrolment in the next year of study, number and dates of exams, suspension of rights and extension of the deadline for completion of studies.

The government also adopted the Conclusion on giving consent that in accordance with the Decree regulating measures for the prevention and control of infectious disease COVID - 19, the Republic of Serbia accepts on the basis of factual reciprocity certificates of full vaccination against COVID - 19 issued by the competent authorities or institutions of the Republic of Cuba and the Islamic Republic of Mauritania and allow entry into the Republic of Serbia to persons holding certificates issued by the competent authorities or institutions of these countries, without a negative PCR test to the presence of SARS-COV-2 or RAPID FIA antigen test.

The decision on reciprocity refers to the following vaccines: AstraZeneca, Sinopharm, Pfizer BioNTech, Janssen, Moderna, Sinovac and Covishield.